Emami vs Zydus Wellness vs Honasa Consumer: Which Stock Should You Track
- September 28, 2026
- Posted by: Harsh Piplani
- Category: Market
Emami PE 22.65, mkt cap Rs 16,989 crore. Zydus Wellness PE 87.69, mkt cap Rs 16,516 crore. Honasa Consumer PE 60.86, mkt cap Rs 15,178 crore.
Quick Answer
Emami vs Zydus Wellness vs Honasa Consumer is a side-by-side comparison of three companies from the Personal Care and FMCG space. On this comparison, Emami carries a market capitalisation of about Rs 16,989 crore against Rs 16,516 crore for Zydus Wellness and Rs 15,178 crore for Honasa Consumer, with return on equity of 26.51%, 3.98% and 14.16% respectively. Each company’s numbers are presented here without a declared better pick, since the right stock depends on an investor’s own criteria.
Emami vs Zydus Wellness vs Honasa Consumer starts with the core numbers most investors compare within the Personal Care and FMCG segment: market capitalisation, valuation multiples, profitability and dividend yield. Figures below are sourced as of September 2026 and will shift with daily price moves.
All three names sit in the Personal Care and FMCG bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses.
Click Here – Get Free Investment Predictions
Emami, Zydus Wellness and Honasa Consumer: Company Overview
Emami is a listed Indian company in the Personal Care and FMCG space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.
Zydus Wellness is a listed Indian company in the Personal Care and FMCG space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.
Honasa Consumer is a listed Indian company in the Personal Care and FMCG space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.
Emami vs Zydus Wellness vs Honasa Consumer: Valuation and Profitability Snapshot
| Metric | Emami | Zydus Wellness | Honasa Consumer |
|---|---|---|---|
| Market Cap (approx.) | Rs 16,989 crore | Rs 16,516 crore | Rs 15,178 crore |
| PE Ratio (TTM) | 22.65 | 87.69 | 60.86 |
| PB Ratio | 5.81 | 2.83 | 10.75 |
| Return on Equity (ROE) | 26.51% | 3.98% | 14.16% |
| EPS (TTM, Rs) | 17.18 | 5.92 | 7.65 |
| Dividend Yield | 2.57% | 0.23% | 0.64% |
| Debt to Equity | 0.06 | 0.55 | 0.10 |
| Book Value per Share (Rs) | 66.99 | 183.12 | 43.33 |
Check the Univest Screener for Live Data
On valuation, Emami trades at a PE of 22.65 and a PB of 5.81, Zydus Wellness at a PE of 87.69 and a PB of 2.83, while Honasa Consumer trades at a PE of 60.86 and a PB of 10.75. On return on equity, the three post 26.51%, 3.98% and 14.16% respectively, and on dividend yield they stand at 2.57%, 0.23% and 0.64%.
Emami vs Zydus Wellness vs Honasa Consumer: Latest Quarterly Results
| Company | Latest Quarter Revenue | Latest Quarter Net Profit | YoY Change (Revenue) | QoQ Change (Revenue) |
|---|---|---|---|---|
| Emami | Rs 1,057.71 crore | Rs 138.94 crore | +14.3% | +11.5% |
| Zydus Wellness | Rs 1,440.80 crore | Rs 118.90 crore | +66.8% | -3.0% |
| Honasa Consumer | Rs 778.46 crore | Rs 90.45 crore | +25.7% | +15.2% |
Quarterly figures above are the most recent reported quarter for each company (Q1 FY27, quarter ended June 2026), compared with the year-ago and preceding quarter.
Download the Univest iOS App or Univest Android App to track Emami, Zydus Wellness and Honasa Consumer live prices.
What Should Investors Look at Beyond These Numbers?
Beyond the metrics above, investors comparing these three personal care and fmcg names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and any sector-specific regulatory developments, since a single-quarter snapshot can shift quickly.
Conclusion
Emami vs Zydus Wellness vs Honasa Consumer highlights how differently three companies in the same personal care and fmcg segment can score across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.
Disclaimer: Data and figures in this article are sourced from publicly available information as of September 2026 and may not reflect real-time prices. Please verify all data independently before making any investment decision. This comparison does not recommend or endorse any single stock over another; investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Emami vs Zydus Wellness vs Honasa Consumer
What is the market cap difference between Emami, Zydus Wellness and Honasa Consumer?
Ans. As of September 2026, Emami has a market cap of approximately Rs 16,989 crore, Zydus Wellness is at approximately Rs 16,516 crore, and Honasa Consumer is at approximately Rs 15,178 crore.
Which of the three has the highest PE ratio?
Ans. Among Emami, Zydus Wellness and Honasa Consumer, the PE ratios stand at 22.65, 87.69 and 60.86 respectively as of September 2026.
Which of the three has the highest ROE?
Ans. Emami, Zydus Wellness and Honasa Consumer post ROE of 26.51%, 3.98% and 14.16% respectively as of September 2026.
Which of these three stocks pays the highest dividend yield?
Ans. Emami, Zydus Wellness and Honasa Consumer carry dividend yields of 2.57%, 0.23% and 0.64% respectively.
What is the debt to equity ratio for Emami, Zydus Wellness and Honasa Consumer?
Ans. Emami carries a debt to equity of 0.06, Zydus Wellness of 0.55, and Honasa Consumer of 0.10.
Which of the three trades at the highest price to book value?
Ans. Emami, Zydus Wellness and Honasa Consumer trade at price to book ratios of 5.81, 2.83 and 10.75 respectively.
Is one of Emami, Zydus Wellness or Honasa Consumer better than the others?
Ans. This comparison does not declare one stock better than another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor’s own criteria and research.
